Denali Therapeutics (DNLI) Cash from Operations (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Cash from Operations of 131204000.0 for Q1 2026, little changed year-over-year from 130941058.15 in Q1 2025, and down 33.15% quarter-over-quarter from 98538000.0 in Q4 2025.
Powered by 
Analysis
Denali Therapeutics (DNLI) Cash from Operations (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Cash from Operations for 10 consecutive years, with 131204000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations changed 0.2% year-over-year to 131204000.0; the TTM figure through Mar 2026 stood at 412336000.0 (down 12.8% YoY), while the FY2025 annual figure was 412600000.0, down 18.67% from the prior year.
- Cash from Operations declined to 131204000.0 in Q1 2026 per DNLI's latest filing, from 98538000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 42898000.0 in Q2 2022 and bottomed at 131468000.0 in Q1 2025.
- Historically, Cash from Operations has averaged 87894411.76 across 5 years, with a median of 87363000.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Operations tumbled 163.81% — and 2024, when it jumped 32.31%.
- Denali Therapeutics' Cash from Operations stood at 72663000.0 in 2022, then slumped by 35.77% to 98657000.0 in 2023, then climbed by 15.15% to 83715000.0 in 2024, then dropped by 17.71% to 98538000.0 in 2025, then sank by 33.15% to 131204000.0 in 2026.
- Business Quant data shows DNLI's Cash from Operations at 131204000.0 in Q1 2026, 98538000.0 in Q4 2025, and 107296000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Denali Therapeutics | 4.18 Bn | 4.18 Bn | 3.51 Mn | -97.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -97.00 Mn |
| Mar 31, 2026 | -131.20 Mn |
| Dec 31, 2025 | -98.54 Mn |
| Sep 30, 2025 | -107.30 Mn |
| Jun 30, 2025 | -75.30 Mn |
| Mar 31, 2025 | -131.47 Mn |
| Dec 31, 2024 | -83.72 Mn |
| Sep 30, 2024 | -59.14 Mn |
| Jun 30, 2024 | -91.22 Mn |
| Mar 31, 2024 | -113.62 Mn |
| Dec 31, 2023 | -98.66 Mn |
| Sep 30, 2023 | -87.36 Mn |
| Jun 30, 2023 | -113.17 Mn |
| Mar 31, 2023 | -58.80 Mn |
| Dec 31, 2022 | -72.66 Mn |
| Sep 30, 2022 | -57.05 Mn |
| Jun 30, 2022 | -42.90 Mn |
| Mar 31, 2022 | -72.11 Mn |
| Dec 31, 2021 | -65.49 Mn |
| Sep 30, 2021 | -41.43 Mn |